ArticleEuropean journal of medical research2025
Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages.European journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to explore the factors affecting pathologic complete response (pCR) and prognosis of locally advanced prostate cancer (LAPCa) or metastatic prostate cancer (mPCa) treated with neoadjuvant androgen deprivation therapy (ADT) with abiraterone acetate (AA).
methodsThis retrospective study enrolled patients diagnosed with LAPCa or mPCa who were divided into three groups based on prostate-specific antigen (PSA) nadir following ADT with AA: group 1 (PSA ≤ 0.2 ng/ml), group 2 (PSA 0.2-4.0 ng/ml), and group 3 (PSA > 4.0 ng/ml). Univariate and multivariate logistic regression models were utilized to investigate the relationship between the variables and pCR, and risk factors of castration-resistant prostate cancer (CRPC).
resultsAmong 79 enrolled patients, 33 (41.8%) patients presented with tumor downstaging and 12 (15.2%) patients presented with pCR. PSA nadir was an independent risk factor for tumor downstaging and pCR. Total 71 (89.87%) patients developed CRPC. The median progression time to CRPC in group 1, 2, and 3 was 28, 26, and 24.5 months, respectively. Compared to control group, patients with tumor downstaging, pCR, or PSA nadir < 0.2 ng/ml had better progression-free survival. Tumor downstaging, pCR, and PSA nadir were independent risk factors for progression to CRPC in LAPCa or mPCa.
conclusionFor patients with LAPCa or mPCa after neoadjuvant AA plus ADT, PSA nadir help predict tumor downstaging or pCR. The patients with tumor downstaging, pCR, or PSA nadir < 0.2 ng/ml have a longer progression time to CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.